BioSpace News Archive

Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of new automated co-detection assays specifically designed for the Roche DISCOVERY ULTRA Platform, enabling simultaneous detection of RNA and protein on the same tissue section.

Provention Bio, Inc. (Nasdaq: PRVB) (the “Company”), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention’s lead investigational drug candidate teplizumab.

RELIEF THERAPEUTICS Holding SA announced that it has hired a leading national health services company to serve as exclusive distributor of PKU GOLIKE ® in the U.S. PKU GOLIKE ® is a next generation medical food product engineered with the patent protected, pharmaceutical grade Physiomimic™ technology for the dietary management of phenylketonuria, and has been commercialized in the EU since 2019.

Global life sciences leader Cytiva has acquired CEVEC Pharmaceuticals, a leading German provider of high-performance cell line development and viral vector manufacturing technologies.

Poolbeg Pharma has been notified that Chief Executive Officer, Jeremy Skillington, has purchased 718,733 ordinary shares of 0.02 pence each in the Company at a share price of 4.78 pence per share.

Nexstim Plc announces that Drs. Lauren Marangell and Rayan Al Jurdi, experts in the treatment of major depression, have purchased a NBS 5+ system.

Tessa Therapeutics Ltd. announced that Thomas Willemsen, President and CEO, Wilson W. Cheung, Chief Financial Officer, and Ivan D. Horak, M.D., Chief Medical Officer and Chief Scientific Officer, will participate in the 2nd Annual Needham Biotech Private Company 1x1 Forum being held virtually October 18-19 2022.

Rectify Pharmaceuticals, Inc. , (“Rectify”) a biotechnology company developing small molecule disease-modifying therapeutics that restore and enhance ABC transporter function, continues to grow its senior leadership team.

Upstream Bio today announced the appointment of three clinical advisors and new leadership additions.

AngioDynamics, Inc. today announced financial results for the first quarter of fiscal year 2023, which ended August 31, 2022.